FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal tumor types worldwide. BET inhibitors display anti-tumor activity in pancreatic cancer, however the cells often develop resistance after a long-term treatment and the underlying molecular basis is not fully understood. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bo, Fan, Ping, Zhao, Jingyuan, Wu, Heyu, Jin, Xin, Wu, Heshui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131902/
https://www.ncbi.nlm.nih.gov/pubmed/30201002
http://dx.doi.org/10.1186/s13046-018-0888-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131902/
https://www.ncbi.nlm.nih.gov/pubmed/30201002
http://dx.doi.org/10.1186/s13046-018-0888-y

Ejemplares similares